Senseonics launches Eversense implantable glucose monitor

Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S.

The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey.

Senseonics’ 90-day, implantable CGM won FDA approval in June this year. The Eversense system includes a small sensor that is implanted just below the skin in an outpatient procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range.

“Since receiving FDA approval for the Eversense System, we have experienced tremendous support and interest from physicians and their patients,” president & CEO Tim Goodnow said in prepared remarks. “We are thrilled that clinics and users can now benefit from Eversense, and we’re also pleased to receive our first medical policy coverage, clearing the way so more people with diabetes can access this important tool for helping ease the burden of managing diabetes.”

“We are pleased to be one of the first clinics to offer Eversense to our patients after our onboard training,” Dr. Bruce Bode, Atlanta Diabetes Associates and associate professor of medicine at Emory University, added. “I have seen the benefits of CGM in my own practice, and it’s important to me to offer the latest technology to my patients. With an implantable long-term sensor, patients with diabetes can have discretion when they want it, the convenience of vibratory alerts from the transmitter, and the comfort of knowing where their glucose is headed.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.